299 related articles for article (PubMed ID: 29460266)
21. PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.
Saavedra A; García-Martínez JM; Xifró X; Giralt A; Torres-Peraza JF; Canals JM; Díaz-Hernández M; Lucas JJ; Alberch J; Pérez-Navarro E
Cell Death Differ; 2010 Feb; 17(2):324-35. PubMed ID: 19745829
[TBL] [Abstract][Full Text] [Related]
22. RTP801 Is Involved in Mutant Huntingtin-Induced Cell Death.
Martín-Flores N; Romaní-Aumedes J; Rué L; Canal M; Sanders P; Straccia M; Allen ND; Alberch J; Canals JM; Pérez-Navarro E; Malagelada C
Mol Neurobiol; 2016 Jul; 53(5):2857-2868. PubMed ID: 25876513
[TBL] [Abstract][Full Text] [Related]
23. Proximity labeling of endogenous RICTOR identifies mTOR complex 2 regulation by ADP ribosylation factor ARF1.
Luciano AK; Korobkina ED; Lyons SP; Haley JA; Fluharty SM; Jung SM; Kettenbach AN; Guertin DA
J Biol Chem; 2022 Oct; 298(10):102379. PubMed ID: 35973513
[TBL] [Abstract][Full Text] [Related]
24. Loss of
Babaev VR; Huang J; Ding L; Zhang Y; May JM; Linton MF
Front Immunol; 2018; 9():215. PubMed ID: 29487597
[TBL] [Abstract][Full Text] [Related]
25. Herp Promotes Degradation of Mutant Huntingtin: Involvement of the Proteasome and Molecular Chaperones.
Luo H; Cao L; Liang X; Du A; Peng T; Li H
Mol Neurobiol; 2018 Oct; 55(10):7652-7668. PubMed ID: 29430620
[TBL] [Abstract][Full Text] [Related]
26. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
[TBL] [Abstract][Full Text] [Related]
27. Twist1 Plays an Anti-apoptotic Role in Mutant Huntingtin Expression Striatal Progenitor Cells.
Jen WP; Chen HM; Lin YS; Chern Y; Lee YC
Mol Neurobiol; 2020 Mar; 57(3):1688-1703. PubMed ID: 31813126
[TBL] [Abstract][Full Text] [Related]
28. microRNA-153 Targets mTORC2 Component Rictor to Inhibit Glioma Cells.
Cui Y; Zhao J; Yi L; Jiang Y
PLoS One; 2016; 11(6):e0156915. PubMed ID: 27295037
[TBL] [Abstract][Full Text] [Related]
29. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
[TBL] [Abstract][Full Text] [Related]
30. Atg4b-dependent autophagic flux alleviates Huntington's disease progression.
Proenca CC; Stoehr N; Bernhard M; Seger S; Genoud C; Roscic A; Paganetti P; Liu S; Murphy LO; Kuhn R; Bouwmeester T; Galimberti I
PLoS One; 2013; 8(7):e68357. PubMed ID: 23861892
[TBL] [Abstract][Full Text] [Related]
31. Selective neuronal degeneration in Huntington's disease.
Cowan CM; Raymond LA
Curr Top Dev Biol; 2006; 75():25-71. PubMed ID: 16984809
[TBL] [Abstract][Full Text] [Related]
32. Two conserved glycine residues in mammalian and
Pergolizzi B; Panuzzo C; Ali MS; Lo Iacono M; Levra Levron C; Ponzone L; Prelli M; Cilloni D; Calautti E; Bozzaro S; Bracco E
J Cell Sci; 2019 Nov; 132(22):. PubMed ID: 31653780
[TBL] [Abstract][Full Text] [Related]
33. The role of RICTOR downstream of receptor tyrosine kinase in cancers.
Jebali A; Dumaz N
Mol Cancer; 2018 Feb; 17(1):39. PubMed ID: 29455662
[TBL] [Abstract][Full Text] [Related]
34. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
35. mTORC2 (Rictor) in Alzheimer's Disease and Reversal of Amyloid-β Expression-Induced Insulin Resistance and Toxicity in Rat Primary Cortical Neurons.
Lee HK; Kwon B; Lemere CA; de la Monte S; Itamura K; Ha AY; Querfurth HW
J Alzheimers Dis; 2017; 56(3):1015-1036. PubMed ID: 28035937
[TBL] [Abstract][Full Text] [Related]
36. Rictor/mTORC2 loss in osteoblasts impairs bone mass and strength.
Liu DM; Zhao L; Liu TT; Jiao PL; Zhao DD; Shih MS; Tao B; Sun LH; Zhao HY; Liu JM
Bone; 2016 Sep; 90():50-8. PubMed ID: 27262777
[TBL] [Abstract][Full Text] [Related]
37. Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.
Saavedra A; Giralt A; Rué L; Xifró X; Xu J; Ortega Z; Lucas JJ; Lombroso PJ; Alberch J; Pérez-Navarro E
J Neurosci; 2011 Jun; 31(22):8150-62. PubMed ID: 21632937
[TBL] [Abstract][Full Text] [Related]
38. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease.
García-Martínez JM; Pérez-Navarro E; Xifró X; Canals JM; Díaz-Hernández M; Trioulier Y; Brouillet E; Lucas JJ; Alberch J
J Neurosci Res; 2007 Sep; 85(12):2756-69. PubMed ID: 17387706
[TBL] [Abstract][Full Text] [Related]
39. Cholinergic neuronal defect without cell loss in Huntington's disease.
Smith R; Chung H; Rundquist S; Maat-Schieman ML; Colgan L; Englund E; Liu YJ; Roos RA; Faull RL; Brundin P; Li JY
Hum Mol Genet; 2006 Nov; 15(21):3119-31. PubMed ID: 16987871
[TBL] [Abstract][Full Text] [Related]
40. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
